AllPennyStocks.com CRSP Stock Slips 3% Despite ‘Encouraging’ CTX310 Data — Morgan Stanley Says Investor Focus Is Further Ahead
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

CRSP Stock Slips 3% Despite ‘Encouraging’ CTX310 Data — Morgan Stanley Says Investor Focus Is Further Ahead

Morgan Stanley expects investor focus to shift to readouts from the next part of the same trial in patients with severe hypertriglyceridemia due in the back half of the year and other second-half readouts.

Other Penny Stock Movers

Fake Players Are Shaping How Games Get Reviewed; This Microcap Just Got Hired to Prove It
Copper's Real Constraint Isn't Demand. It's Ground
Colombian Oil Producer Jumps as Q2 Revenue More Than Doubles
Most Popular
{{ index + 1 }}


Back to Top